The generation of oxidized phospholipids in lipoproteins has been linked to vascular inflammation in atherosclerotic lesions. Products of phospholipid oxidation increase endothelial activation, however their effects on macrophages are poorly understood and it is unclear whether these effects are regulated by the biochemical pathways that metabolize oxidized phospholipids. We found that incubation of 1-palmitoyl-
INTRODUCTION
Cardiovascular diseases have become the leading cause of death in the world. A majority of cardiovascular diseases is due to atherosclerosis, which is underlying pathology associated with 70-75% of all cardiovascular deaths (1) . Atherosclerosis is a chronic inflammatory state associated with the formation of characteristic vascular lesions rich in cholesterol, macrophages, and proliferating smooth muscle cells (2, 3) . Occasionally, these plaques rupture or erode and thereby prevent blood flow to target tissue by forming occlusive thrombi. A key initiating event in the process of atherogenesis is the vascular recruitment of monocytes by lipoproteins trapped within the vessel wall. It is currently believed that once lodged within the sub-intimal space, the lipoproteins undergo non-enzymatic oxidation, which generates bioactive products that cause inflammation and promote monocyte recruitment. Investigations into the nature of these bioactive products have shown that most of the biological activity of oxidized lipoproteins could be attributed to the products of phospholipid oxidation generated within the lipoprotein particle (4, 5) .
Oxidation of phospholipids results in the generation of several metastable end-products. In LDL, the most abundant products are those that are derived from the oxidation of 1-palmitoyl-2-arachidonoyl-snglycero-3-phosphocholine (PAPC). PAPC is the major phospholipid present in LDL and the oxidation of its sn-2 arachidonic acid chain results in the formation of several carbonyl compounds of which 1-palmitoyl-2-(5'-oxo-valeroyl)-sn-glycero-3-phosphocholine (POVPC) (Scheme 1A) is generated in the highest concentration (5) . POVPC is the most reactive phospholipid generated in oxLDL and the overall biological reactivity of oxLDL is dominated by its POVPC content (6) .
Extensive evidence supports the view that POVPC and related phospholipids play an important role in atherogenesis. These phospholipids have been detected in oxidized LDL and atherosclerotic lesions of humans, rabbits and mice (7, 8) and high titers of antibodies against POVPC and other lipid oxidation products develop in apoE-null mice (8) . Significantly, the circulating levels of POVPC-bound apoB correlate strongly with coronary artery disease (9) and reflect the extent of carotid and femoral atherosclerosis (10) , suggesting that the generation of oxidized phospholipids may be linked to disease progression. In vitro, POVPC activates endothelial cells to bind monocytes (5) and it increases the transcription of cytokine genes such as IL-8 and MCP-1 (11, 12) ; therefore it could establish a chronic state of inflammation required for the initiation and the progression of atherosclerotic lesions (4, 13) .
Indeed, topical application of oxidized lipids to carotid arteries in mice increases vascular inflammation (14) .
The high biological activity of POVPC and related phospholipids has been suggested to be due the presence of a short chain at the sn-2 position. This chain is recognized by several cellular receptors and as a result oxidized phospholipids can activate multiple signal transduction events. Our previous studies showed that the sn-2 aldehydes are reduced by enzymes belonging to the aldo-keto reductase (AKR) superfamily (15) . Of these enzymes aldose reductase (AKR1B1, AR) was found to be particularly efficient in catalyzing the reduction of the sn-2 aldehyde of POVPC to the corresponding alcohol.
Nevertheless, it is not known whether metabolism via AR regulates the biological activity of phospholipid aldehydes. Accordingly, the current study was designed to develop a better understanding of the role of AR in regulating the pro-inflammatory effects of POVPC in macrophages. We chose to study macrophages, because these cells have been shown to play an obligatory role in lesion development (16) .
Our results show that macrophages respond to POVPC by strongly upregulating the expression of several cytokine genes and that the induction of these genes is regulated by the metabolism of POVPC via AR.
MATERIALS AND METHODS

Reagents:1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine was purchased from Avanti Polar
Lipids (Alabaster, AL). Solvents and other analytical grade reagents were obtained from Sigma Chemical Co (St. Louis, MO). POVPC, PHVPC, POVPE (1-palmitoyl-2-(5'-oxo-valeroyl)-sn-glycero-3-phosphoethanolamine) and PHVPE (1-palmitoyl-2-(5'-hydroxy-valeroyl)-sn-glycero-3-phosphoethanolamine) were synthesized as described previously (17) . Purity of the phospholipid aldehydes was established by ESI + /MS. Phospholipid concentration was determined by measuring inorganic phosphate or choline. Choline was measured using the Phospholipids C kit (Wako, Osaka, Japan), and inorganic phosphate was measured as described in (18) . Pefabloc was purchased from Pentapharm (Basel, Switzerland). Tolrestat was a gift from American Home Products (Madison, NJ). Cell culture reagents were obtained from Invitrogen (Carlsbad, CA), and plates were from Corning (Union City, CA). RNeasy RNA isolation kit was from Qiagen (Valencia, CA), rDNAse (DNA-free TM Kit) was from Ambion (Austin, TX), AMV Reverse Transcriptase from Promega (Madison, WI), and SYBR Green master mix from Quanta BioSciences (Gaithersburg, MD).
Cell culture: THP-1 cells obtained from the American Type Culture Collection (ATCC) were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum and 1%
penicillin/streptomycin at 37˚C and 5% CO 2 in a humidified incubator. For differentiation into the macrophage-like cells, phorbol 12-myristate 13-acetate (PMA) was added to a final concentration 100 nM in growth media and cells were incubated for 72h. Immortalized murine macrophage cell lines were established by infecting the bone marrow of wild-type C57BL/6J mice and AR-null homozygous mice with the murine recombinant J2 retrovirus containing the v-myc and v-raf oncogenes as described (19) .
The resulting bone-marrow derived macrophage cell lines were cultured in RPMI 1640 supplemented with 5% FBS, 1% HEPES and 0.1% gentamycin.
To measure changes in the expression of cytokine genes, the cells (passages 4-10) were seeded in 6-well plates at 2 million cells per well in 2 ml of media. Before treatment, THP-1 derived macrophages (THP-1 DM) and BMDM were serum-starved overnight in media containing 0.1% FBS. Treatment reagents were dissolved in Hanks balanced salt solution (HBSS, pH 7.4, 20 mM HEPES, 135 mM NaCl, 5.4 mM KCl, 1.0 mM MgCl 2 , 2.0 mM CaCl 2 , 2.0 mM NaH 2 PO 4 , 5.5 mM glucose). For metabolic studies, the cells were seeded in 10 cm dishes at a density of 12 million per 10 ml media. For inhibitor experiments, the cells were pre-incubated in 2.5 ml media containing 50 µM inhibitor in HBSS for 1h before POVPC addition. After incubation for indicated time, the cells were washed twice with HBSS, scraped and resuspended in the lysis buffer.
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Phospholipid analysis: Lipids were extracted from cells or media using Bligh-Dyer procedure (20) .
Briefly, after washing twice with cold HBSS the cells were scraped from the plate in 0.9% NaCl in water and transferred into a glass tube; and the volume was adjusted to 200 µl. To this, 500 µl methanol containing 750 pmol reagent 1,2-dicaproyl-sn-glycerophosphochline was added, followed by the addition of 250 µl chloroform. The solution was incubated at room temperature for 30 min with periodic mixing, after which another 250 µl chloroform and 250 µl 0.9% NaCl were added, and the phases were separated by brief centrifugation. The lower chloroform phase was analyzed by ESI/MS in positive and negative ionization modes using a Micromass ZMD 2000 mass spectrometer (Waters-Micromass, Milford, MA).
2:1 (v/v) methanol/chloroform containing 1% acetic acid was used as the flow injection solvent. Choline or phosphate content in each sample was measured and phospholipids solutions were adjusted to equal concentration (2µg inorganic phosphate per ml) prior to injection into the mass-spectrometer. For the media extraction, 1.25 ml media was used, and all volumes were adjusted accordingly. Injections were carried out using a Harvard syringe pump at a flow rate of 20 µl per min. The ESI + /MS operating parameters were: capillary voltage 3.38 kV, cone voltage 25 V, extractor voltage 9 V, RF lens voltage 0.9 V, source block, and desolvation temperatures 100 and 200 °C, respectively. Nitrogen was used as the nebulizer gas at a flow rate of 3.4 liters/h. Spectra were acquired at a rate of 275 atomic mass units per second over the mass range of 2-1000 atomic mass units and were averaged over a period of 5 min or 100
scans. The amount of phospholipid was quantified using the ratio of the height of its peak to that of the standard (1,2-dicaproyl-sn-glycerophosphochline). In experiments with radioactive POVPC, POVPC labeled at the carbon-1 of the substituent at the sn-2 position with 14 C was added to the incubation media (HBSS) at 1.2 x 10 -7 Ci, 2.4 nmols per 2.5 ml. Lipids were separated from the media and the cells after incubation using the same procedure. Radioactivity was measured in both chloroform and aqueous phases using a Beckman liquid scintillation counter.
For synthesizing 14 qRT-PCR: RNA was isolated using QIAGEN RNeasy kit, according to manufacturer's instructions and treated with rDNase. RNA concentration was measured using the Nanodrop® 1000A Spectrometer.
cDNA was synthesized from 1 µg RNA at 42°C for 1h using oligo(dT) [12] [13] [14] [15] [16] [17] [18] primers and AMV Reverse
Transcriptase. qRT PCR were performed in iCycler equipment (Bio-Rad) using SYBR Green detection. 
RESULTS
POVPC induces expression of proinflammatory cytokines:
Previous studies show that treatment of endothelial cells with POVPC results in the activation of pro-inflammatory signaling (13) . However, the effects of POVPC on macrophages are poorly understood. Although it has been reported that free apoBbound POVPC is a ligand of the scavenger receptor (CD36) (21) , it is unclear how POVPC affects the expression of cytokine genes in macrophages. Hence, we studied the effects of POVPC on the expression of genes involved in macrophage signaling and cytokine production. For this, THP-1-derived macrophages were treated with 10 µM POVPC, and 3h after treatment, gene expression was measured using a RT 2 Profiler TM PCR array. As shown in Fig. 1 Table 2 ). As listed in Table 1 , the expression of several inflammatory genes was increased 10-100 fold. The most inducible genes were pro-inflammatory cytokines such as GM-CSF, TNF-α, and IL-8, and the expression of these genes was increased 100-, 60-and 50-fold, respectively. Significant increases were also observed in the expression of COX-2, VCAM-1, MMP-1, TRAF2 and IL-1α. Collectively, these data indicate that POVPC establishes a proinflammatory state in macrophages characterized by the induction of genes regulated by the NF-κB pathway leading to the upregulation of cytokines, chemokines and COX-2. Given that TNF-α and IL-8 were most responsive to POVPC, we examined changes in these genes to study how metabolism regulates inflammation.
Metabolites of POVPC generated in THP-1 macrophages:
To assess how POVPC-induced changes in pro-inflammatory genes are regulated by metabolism, we investigated POVPC metabolism in macrophages. For this we identified the major POVPC metabolites generated in macrophages, and the metabolic pathways involved in their generation. We also studied the inter-relationship between these pathways.
To identify metabolites, serum-starved differentiated THP-1 cells were incubated with 10 µM To establish chemical identity of POVPC metabolites, the phospholipid extract from the cells was separated by HPLC and the ions at m/z 496, 594, and 596 were followed using online mass-spectrometer.
The retention times and the separation pattern matched closely with that of the standard compounds ( separately. Each of these was then extracted using the Bligh and Dyer procedure and radioactivity in both the aqueous and the chloroform extracts of each fraction was measured. Our results showed that after 5 min of incubation, 61% of total radioactivity (cells+media) was in the aqueous extract and the rest in the chloroform fraction, indicating that POVPC was incorporated in the cells and readily hydrolyzed. The excised sn-2 chain is then extruded from the cells into the medium (Fig. 3A) . After 30 min of incubation, 83% of the radioactivity was associated with aqueous extract of the medium (Fig. 3A) . In the chloroform fraction, the ratio of radioactivity found in the medium to that in cells was 2:1, indicating that most of the POVPC was sequestered in cells (the volume of cells is several orders of magnitude smaller than the volume of the media), whereas cleaved product -glutaryl semialdehyde is present mostly in media. Mass spectrometric measurements of phospholipids in the cell and media extracts after 5 and 30 min of treatment showed distribution of POVPC between the cells and the media matching radioactivity measurements in the chloroform fraction (Fig. 3B ). Between 5 and 30 min there was a significant decrease in the amount of cell-associated radioactivity; consistent with the view that 14 C-glutaryl semialdehyde generated by hydrolysis is extruded from the cells to the medium. Collectively, these results indicate that in THP-1 macrophages reduction and hydrolysis are the two major pathways of POVPC metabolism and that ultimately most (>80%) of POVPC is hydrolyzed to lyso-PC.
Biochemical pathways of POVPC metabolism:
Conversion of POVPC to PHVPC and lyso-PC may be due to two independent competing pathways (Scheme 1BI) or a series of interdependent metabolic transformations (Scheme 1BII), in which conversion to PHVPC may (k 2 =0) or may not (k 2 ≠0) be required for hydrolysis. To distinguish between these possibilities, the cells were pretreated with pefabloc, an inhibitor of PLA 2 , in order to examine whether PLA 2 inhibition would affect POVPC reduction. The rate of hydrolysis was determined from the difference in radioactive counts in the chloroform fraction remaining after 5 and 30 min incubation ( Next we examined the reductive metabolism of POVPC. Our previous studies show that several AKRs can catalyze POVPC reduction (15) . Although these enzymes show wide tissue distribution, AKR1B1 (AR) is the major AKR expressed in THP-1 cells (data not shown). To study the role of this enzyme, the cells were treated with the AR inhibitor -tolrestat. Treatment with tolrestat inhibited the reduction of POVPC to PHVPC in these cells, as reflected by a significant decrease in the PHVPC:POVPC ratio (Fig. 4 A-C) . Tolrestat, however, had only minor (but positive) effect on hydrolysis (Fig. 3C ), suggesting that both POVPC and PHVPC undergo hydrolysis with a similar efficiency, and the hydrolysis of POVPC may occur somewhat faster than that of PHVPC. Taken together, these data suggest that PLA 2 and AR are the major enzymes involved in the metabolism of POVPC in THP-1 macrophages and that both hydrolysis and reduction compete with each other such that inhibition of hydrolysis increases POVPC reduction.
The observation that pefabloc increased the levels of unmetabolized POVPC indicates that PLA 2 -induced hydrolysis is a significant route of POVPC metabolism. Treatment with tolrestat, however, did not lead to a statistically significant increase in unmetabolized POVPC. This suggests that k 2 is more than k 1 , but it does not help in distinguishing between Scheme I and II or in assessing whether PHVPC is also metabolized by PLA 2 (k 3 ≠0). Hence, to examine how PHVPC is metabolized, we synthesized reagent PHVPC. Treatment of THP-1 cells with PHVPC led to a rapid incorporation of reagent in membrane phospholipids (Fig. 5A) . A gradual decrease in PHVPC content in the cells indicated that it is either metabolized or extruded. To identify whether it is metabolized, the cells were treated with pefabloc before incubation with PHVPC. As shown in Fig. 5A (right panel), treatment with pefabloc led to gradual buildup of unmetabolized PHVPC in the membrane, indicating that like POVPC, PHVPC is also metabolized by PLA 2 . This conclusion supports the view that POVPC metabolism follows Scheme IBII. Moreover, a comparison of the rate of disappearance of POVPC and PHVPC in THP-1 showed that after exogenous addition, the rate of disappearance of POVPC was faster than that of PHVPC, indicating that POVPC is more rapidly metabolized than PHVPC, i.e., k 2 >k 3 ( Fig. 5B ).
Proinflammatory effects of POVPC and its metabolites:
Extensive conversion of POVPC into lyso-PC and PHVPC suggests that the structural transformations induced by this metabolism might significantly impact the biological activity of the parent phospholipid. AR-catalyzed reduction could decrease the chemical reactivity of the sn-2 carbonyl, whereas PLA 2 -mediated hydrolysis, which generates a lyso-phospholipid, could impart new activity to the molecule. Hence, to determine how metabolic conversion affects the biological activity of POVPC, we examined the relative efficacy of POVPC, PHVPC and lysoPC in inducing the expression of the cytokine genes. For this, we selected the genes (TNF-α, IL-8, GM-CSF, IL-1β, MCP-1 and IL-6) that were most strongly induced by POVPC (Table 1 ). Because we expected temporal variation in the extent of induction, we measured time-dependent changes in gene expression. As shown in Fig. 6 , treatment with POVPC led to a rapid increase in the mRNA for TNF-α, IL-8, GM-CSF and IL-1β. The earliest increase was observed with TNF-α.
Maximal induction of the TNF-α gene was observed within 45-90 min of treatment with POVPC. The induction of TNF-α was followed by IL-8, GM-CSF and IL-1β. The increase in the expression of all of these genes displayed nearly maximal induction within 90 min, indicating that these were the early response gene. The expression of the genes for MCP-1 and IL-6 were increased more slowly, potentially as part of a delayed-early response.
In comparison with POVPC, PHVPC and lyso-PC were more effective in increasing the expression of cytokine genes. For example, in cells incubated with POVPC for 45 min there was a 4-7 fold increase in IL-8 and TNF-α, however, in the presence of lyso-PC, the expression of these genes was increased 18-to 33-fold versus untreated cells (Fig. 6 A&B) . PHVPC was even more effective. In cells treated with PHVPC, 33-to 147-fold increase in the expression of both IL-8 and TNF-α was observed. Similar effects were observed with other cytokine genes. In untreated cells, the expression of GM-CSFgranulocyte/macrophage colony-stimulating factor (CSF2), was near the limits of detection. Treatment with POVPC for 3h led to 38-fold increase in the expression of this gene. Under the same conditions, PHVPC was 36 times more potent in inducing GM-CSF than POVPC. Lyso-PC displayed intermediate reactivity (Fig. 6C) . Similarly, the expression of IL-1β was increased 2-to 5-fold in cells treated with POVPC or lyso-PC, whereas treatment with PHVPC led to 30-fold increase in the expression of this gene with 90 min of treatment. The greater reactivity of PHVPC was also evident with MCP-1 and IL-6.
Although both POVPC and lyso-PC were weak inducers, incubation with PHVPC led to a 15-to 150-fold greater increase in the expression of these genes (Fig. 6 E-F) . From these results we conclude that PHVPC is significantly more effective than POVPC in inducing cytokine genes. Lyso-PC is more effective than POVPC, but less potent than PHVPC.
The reactivity of POVPC and PHVPC may be related to their abbreviated sn-2 chains, which imparts these molecules a PAF-like character. However, the biological effects of PAF depend upon the sn-3 phosphocholine head group. Hence to determine the cytokine-inducing ability of POVPC and PHVPC are related to their choline head group, we prepared ethanolamine analogs of POVPC and PHVPC, i.e., POVPE and PHVPE. As shown in Fig. 6G , treatment with POVPE led to a 2-4 fold increase in the expression of IL-1β, IL-8, TNF-α and MCP-1. The extent of increase in the expression of these genes was similar to that observed with POVPC. Moreover, like PHVPC, PHVPE was markedly more potent than POVPE in increasing cytokine gene expression, suggesting that the relative biological activities of these phospholipids are independent of the nature of the head group at the sn-3 position.
Metabolic Regulation of the proinflammatory effects of POVPC:
Our results so far indicated that the metabolites of POVPC are more active than the parent phospholipid. Based on these observations, we
reasoned that inhibition of metabolism should decrease the proinflammatory effects of POVPC. To test this hypothesis, we examined the effects of inhibiting POVPC metabolism on cytokine gene induction.
For these experiments, THP-1 cells were pre-treated with either pefabloc or tolrestat for 1h before the addition of POVPC and changes in the expression of IL-8 gene were measured 3h after POVPC treatment. As before, treatment with POVPC led to a robust induction of IL-8 (Fig. 7) . However, in the presence of pefabloc, the increase in IL-8 was 2-fold greater than in the absence of the inhibitor. This result suggests that inhibition of hydrolysis increases the biological activity of POVPC. Because lyso-PC was more reactive than POVPC (Fig. 6 ), this increase in cytokine gene induction could not be due to the accumulation of unmetabolized POVPC, but may be due to increased accumulation of PHVPC (see Fig.   4 ).
In contrast to pefabloc, treatment with tolrestat led to a significant decrease in IL-8 induction. This observation suggests that inhibition of AR decrease PHVPC levels and therefore diminishes the overall reactivity of POVPC, even though lyso-PC formation is increased. To further confirm that the reactivity of POVPC depends upon PHVPC formation, the cells were treated directly by PHVPC. As before (Fig.   6 ), PHVPC was more potent than POVPC in inducing IL-8, however, in pefabloc-treated cells, PHVPC was almost twice as effective as in untreated cells. The increase in the effect of PHVPC in the presence of pefabloc is consistent with the conclusion that PHVPC is more potent than lyso-PC. We suggest that by inhibiting hydrolysis, pefabloc prevents the removal of PHVPC ( 
DISCUSSION
The major findings of this study are that the products of phospholipid oxidation such as POVPC increase the expression of cell survival and inflammatory genes in macrophages and that metabolism of these aldehydes increases their pro-inflammatory effects. We found that macrophages employ two major pathways to metabolize POVPC and related phospholipid aldehydes. Aldehyde phospholipids are either reduced by AR or they are hydrolyzed by PLA 2 to lyso-phospholipids. However, neither of these metabolic transformations decreases the pro-inflammatory effects of POVPC, instead metabolites of both these pathways -PHVPC and lyso-PC were found to be more effective in inducing cytokine gene expression than POVPC itself. Consistent with higher pro-inflammatory potential of PHVPC and lyso-PC, we found that blocking PLA 2 -mediated hydrolysis leads to an accumulation of PHVPC and an increase in the induction of cytokine genes, whereas, inhibition of AR-mediated reduction led to a decrease in the pro-inflammatory effects of POVPC. Comparative studies showed that PHVPC was nearly an order-of-magnitude more active than either lyso-PC or POVPC; however lyso-PC was more effective than POVPC. These observations provide new information about the mechanisms by which oxidized phospholipids induce inflammation and how their pro-inflammatory effects are regulated by metabolic transformation.
Previous studies suggest that phospholipid aldehydes generated during lipid oxidation play a key role in atherogenesis (4, 13). The process of atherogenesis begins with inflammation localized to lesion-prone areas containing sub-intimal depots of oxidized lipoproteins (2). It is believed vascular inflammation is triggered and maintained by bioactive component of oxidized LDL, particularly phospholipid aldehydes generated by oxygenation and bond-scission of sn-2 esterified unsaturated fatty acids. POVPC has been previously identified as one of the major oxidized phospholipid generated in oxidized LDL (5) and a key mediator of the atherogenic (6) and immunogenic (8-10, 23) effects of oxidized LDL.
Extensive research has uncovered a large number of cell signaling pathways that are activated by POVPC and related phospholipids (4, 13) . Activation of these pathways leads to either pro-inflammatory or anti-inflammatory effects. In endothelial cells the oxidized phospholipids increase cytokine production and promote monocyte binding. However, consistent with their electrophilic nature oxidized phospholipids also activate Nrf2-dependent signaling (24, 25) resulting in the increase in phase II detoxification enzymes and protective proteins such as HO-1. They can also prevent the activation of NF-κB by TLR4 and thereby prevent lethal endotoxin shock in LPS-injected mice (26) . The antiinflammatory effects of oxidized phospholipids have been linked to their ability to bind directly to accessory proteins (CD15, MD2, and the LPS-binding protein) that interact with bacterial lipids (26, 27) .
However, the mechanisms responsible for the pro-inflammatory effects of oxidized lipids are less clear.
Much of the work has been done in endothelial cells in which oxidized phospholipids increase monocyte binding by activating signaling cascades that involved activation of the src/JAK/PI3Kinase leading to the activation of eNOS and SREBP (4). In macrophages, treatment with POVPC has been shown to increase cytokine production (28), however, the mechanism of this effect remains unclear.
In culture human aortic endothelial cells respond to oxPAPC by up-regulating >1000 genes (29) .
While prominent induction of IL-8 and genes involved in cholesterol metabolism and the unfolded protein response was observed, classical pathways of inflammation were not affected. In contrast, our studies with POVPC-exposed macrophages show a prominent increase in several pro-inflammatory cytokines, such as TNF-α, IL-6, IL-8 and IL-1β that play a central role in inflammation. Thus, there may be fundamental differences in the way with which different cells respond to oxidized phospholipids.
Whereas endothelial cells seem to respond by increasing adhesion and cholesterol metabolism, the response in macrophages seem to be predominantly an increase in the expression of several cytokine genes. We found that exposure to POVPC upregulated the genes of several cytokines. The findings of the current study demonstrate that the nature and the extent of inflammatory responses elicited by POVPC depend upon macrophage metabolism. POVPC and related phospholipids have an unusual sn-2 group, which due to its unique structure alter membrane fluidity by disrupting the packing order of fatty acid chains in the phospholipid bilayer (38) . The nature of this group is also important for the recognition of oxidized phospholipids by the PAF-receptor, scavenger receptor B-I or CD36 (39, 40) . Thus changes in the structure of the sn-2 group during metabolism could drastically affect the biological activity of these phospholipids. Chemically, the sn-2 chain could be completely removed from the phospholipid by hydrolysis or its ω-carbonyl could be enzymatically reduced or oxidized. In case of POVPC, we found that hydrolysis and reduction were the two major fates of the phospholipid. No oxidative metabolism was detected in macrophage, although oxidation by aldehyde dehydrogenases remains an untested possibility in other cell types.
Hydrolysis of POVPC and related oxidized phospholipids with an abbreviated sn-2 chain has been shown to be catalyzed by PAF-acetylhydrolase (PAF-AH; group VIIA PLA 2 ). Two major forms of the enzyme have been described (41) . The plasma form is secreted by cells of hematopoietic origin and is associated with circulating lipoproteins (Lp-PLA 2 ). The intracellular cytosolic form is expressed mainly in hepatocytes and epithelial cells of kidney and intestine (42) . These phospholipases display high activity with sn-2 oxidized chains of phospholipids. In atherosclerotic lesions, Lp-PLA 2 is predominantly associated with macrophages localized to the lipid pool or the necrotic core of the lesion (43). Our results
showing for the first time that POVPC is extensively hydrolyzed in macrophages and that this hydrolysis is prevented by the serine esterase inhibitor -pefabloc indicate that macrophage PLA 2 plays a major role in the metabolism of oxidized phospholipids in macrophages.
In our study, hydrolysis of POVPC resulted in the formation of a lyso-PC, which was found to be more potent in stimulating cytokine production than POVPC, indicating that metabolism via PLA 2 may be important in increasing the pro-inflammatory effects of oxidized lipids. In clinical studies, Lp-PLA 2 is a robust predictor of cardiovascular disease risk independent of the established risk factors (41) and it has been suggested that under some clinical or experimental scenarios Lp-PLA 2 may be a causal mediator of atherogenesis. Treatment of patients with angiographically documented coronary disease with the PLA 2 inhibitor -darapladib has been reported to decrease the necrotic core volume of the plaque, a key determinant of plaque stability (44) . Similarly, in a porcine model of diabetes and hypercholesterolemia, treatment with the PLA 2 inhibitor SB677116 was found to decrease inflammation and vascular accumulation of inflammatory cells (45) . In contrast to these proatherogenic effects, PLA 2 has also been associated with a decrease in inflammation and a decrease in atherosclerotic lesion formation. For instance, gene transfer of Lp-PLA 2 in apoE-null mice led to a decrease in the deposition of oxidized lipoproteins and a reduction in atherosclerotic lesion formation in male but not in female mice (46) .
Similarly local delivery of the Lp-PLA 2 gene at the site of injury decreases neointima formation in balloon-denuded aorta in cholesterol-fed rabbits (47) and inhibits the accumulation of oxidized lipoproteins and inflammation in normolipidemic rabbits (48) . In addition, overexpression of PAF-AH in cells suppresses oxidative stress-induced cell death (49) , whereas tissues from Pafah2-null mice display higher sensitivity to peroxide injury than those derived from WT mice (42) .
Several reasons could account for the apparently contradictory effects of PLA 2 on inflammation and atherosclerosis. Difference may arise due to different study protocols, the location, association or the extent of expression of the enzyme and the disease state, model and characteristics examined in the study.
However, in all scenarios, the product of PLA 2 hydrolysis of oxidized phospholipid will be a lysophospholipid, which in itself is not an innocuous metabolite. It induces apoptosis in endothelial cells (50) and it activates monocytes by increasing their production of inflammatory cytokines (IL-1β, IL-6 and TNF-α) (45) . Our results support the inflammatory properties of lyso-PC, but more importantly, we demonstrate, for the first time, that lyso-PC is more active than the parent aldehyde phospholipid POVPC.
This finding suggests that the metabolism via PLA 2 could increase inflammation at least in macrophages exposed to oxidized phospholipids. Although the activities of other oxidized phospholipids relative to their lyso-phospholipids were not examined, the observation that inhibition of PLA 2 abrogates the inflammatory responses to oxidized LDL in monocytes suggest that the overall effect of the hydrolysis of oxidized phospholipids by PLA 2 is to increase rather than decrease inflammation.
Even though its products (lyso-phospholipids) have greater inflammatory activity than parent phospholipids, PLA 2 could potentially prevent both inflammation and atherosclerosis. We found that inhibition of PLA 2 increased the accumulation of PHVPC. Because PHVPC was more active than either lyso-PC or POVPC, it is likely that under some conditions inhibition of PLA 2 could exacerbate inflammation, if there is a subsidiary pathway of metabolism that enhances the biological activity of the oxidized phospholipid. Thus a significant conclusion from our work is that PLA 2 is not the only biochemical pathway for the metabolism of oxidized lipids and that there may be subsidiary, but interdependent, pathways of metabolism that could significantly and robustly modify the effects of oxidized lipids and the role of PLA 2 in regulating both inflammation and atherosclerosis.
In case of macrophages, this subsidiary pathway was catalyzed by AR. This enzyme has broad substrate specificity and near ubiquitous expression (51). Our previous studies have shown that AR and related members of the AKR superfamily are efficient catalysts for the reduction of POVPC and other phospholipid aldehydes (15, 17) . The current work confirms this activity and extends it to the metabolism of POVPC in macrophages. In addition, we found that the AR-catalyzed pathway competes with PLA 2 hydrolysis for the POVPC metabolism, but the product of this pathway -PHVPC -is also hydrolyzed by PLA 2 . Thus, even though the eventual fate of POVPC is hydrolysis, the side reaction with AR serves to increase the inflammatory capacity of the phospholipid. Therefore, reduction by AR could be viewed as a sensory pathway by which the inflammatory effect of oxidized phospholipids could be amplified. The inflammation-enhancing role of this pathway is consistent with previous studies showing that inhibition of AR prevents NF-κB activation (52) and cellular or systemic inflammation induced by high glucose (53), TNF-α (54) or LPS (55). In agreement with these findings, we observed that inhibition of AR led to a significant suppression of POVPC-induced cytokine production. Nevertheless, how the products of AR such as PHVPC trigger changes in cytokine gene expression remains unknown.
Because PHVPC retains the PAF-like structure of the molecule, it could be speculated that PHVPC is also recognized by the same receptors as POVPC (CD36, SRB-I, PAF-R) and because of the loss of the reactive ω-carbonyl, it is less likely to react non-enzymatically with cellular nucleophiles, PHVPC may be a more stable ligand of these receptors than POVPC. Indeed, our studies show that the life-time of PHVPC in macrophage was significantly longer than that of POVPC (Fig. 5C ), indicating that it may cause a stronger and/or more sustained activation of cellular receptors than POVPC.
The efficacy of the reductive metabolism of POVPC in mediating inflammatory changes is likely to depend upon the relative level of expression and activity of both AR and PLA 2 rather than the absolute activity of each of this enzyme. Thus, even in cells replete with AR, the extent of inflammation induced will be minimal if these cells also express high levels of PLA 2 and vice versa. In addition, the levels of the specific receptors that recognize lyso-PC and PHVPC will be important. In cells that lack receptors for PHVPC or lyso-PC, but not those that recognize POVPC, metabolism via PLA 2 or AR may actually lead to decrease in inflammation. For instance, in contrast, to the pro-inflammatory effect of lyso-PC and PHVPC described here, Subbanagounder et. al., have reported that hydrolysis by PLA 2 or reduction by sodium borohydride led to a significant decrease in the ability of POVPC to enhance leukocyteendothelial interactions (6) . Thus it is possible that different cells sense the presence of oxidized phospholipids by different mechanisms and that the difference in metabolic pathways or cellular receptors allows them to respond differently to oxidized phospholipids. As a result, the in vivo effects of the oxidized phospholipids on inflammation are difficult to predict from direct extrapolation of in vitro data.
There is even greater difficulty in evaluating the in vivo atherogenic significance of this metabolism and its inflammatory consequences. The relationship between inflammation and atherogenesis is complex, and although high levels of inflammation in advanced lesions is associated in an increase in plaque vulnerability, inhibition of inflammation does not always decrease lesion formation. For example in LDL-R null mice, inhibition of NF-κB in macrophages decreases atherosclerotic lesion formation (56), whereas IL-6 null mice develop more fatty streaks than WT mice (57). Similarly, despite the clear inflammation enhancing effects of PLA 2 and AR in macrophages reported here, atherosclerotic lesion formation is higher in AR and apoE-null mice than in WT-apoE-null mice (58) and Lp-PLA 2 gene transfer reduces spontaneous atherosclerosis (46) . Clearly, extensive additional investigations are required to fully understand how inflammation contributes to atherosclerotic lesion formation and how it is triggered by oxidized phospholipids and regulated by their metabolism.
In summary, the results of this study show that in macrophages phospholipid aldehydes such as POVPC are metabolized by two distinct, but interrelated metabolic pathways catalyzed by PLA 2 and AR.
Products of both these pathways (lyso-PC and PHVPC) were more effective in inducing the expression of Changes in the levels of mRNA of cytokine genes were measured by quantitative RT-PCR as described in 
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